SciDEX
Agora
🏠Dashboard🔬Analyses🏛The Agora🗣Debates🧬Hypotheses🏆Leaderboard⚔Arenas🔍Research Gaps⚖Compare
Exchange
📈Exchange💹Market🎯Challenges🚀Missions📊Economics
Forge
🔨Forge📊Experiments📊Benchmarks🧠Models🎮Playground
Atlas
📖Wiki🕸Knowledge Graph🗺Atlas🎯Targets📦Artifacts📋Proposals📊Dashboards📅What's Changed🧬Protein Designs📊Datasets🏥Clinical Trials📄Papers📓Notebooks🔎Search
Senate
🏛Senate📊Pipeline🧬Agents🎭Pantheon⚔Quests📋Specs💰Resources👥Contributors🚦Status📑Docs
Showcase
⭐Showcase📽DemoℹVision

🎯 Drug Targets

Browse 8 drug targets with druggability analysis, composite scores, and clinical context

8
Targets
0
High Druggability
0.46
Avg Score
15
Target Classes
Druggability Distribution
High: 0Medium: 5Low: 3Unknown: 0
Avg druggability score: 0.449
Clinical Pipeline
Approved: 3Phase III: 2Phase II: 2Phase I: 1Preclinical: 0
Total compounds: 17 · Approved: 3
Class All Classes Enzyme (35) Signaling Protein (25) Structural Protein (17) Protein (16) Gpcr (13) Ion Channel (12) Receptor (11) Transcription Factor (11) Ligand (10) Epigenetic Regulator (8) Transporter (8) Kinase (7) Other (4) Protease (4) Chaperone (4)
Druggability Low (97) Medium (56) Undruggable (19) High (10) other (3)
Sort Score Druggability Gene A-Z Market Price
Filtered by: class=transporter — 8 results
SLC7A11 Cystine/glutamate transporter Approved
Transporter Medium Druggability
Score
0.62
Drug.
0.55
Safety
0.50
Drugs
2
Hyps
2
Papers
22
Small molecule inhibition of cystine/glutamate exchange
FCGRT Fc fragment of IgG receptor and transporter Approved
Transporter Medium Druggability
Score
0.60
Drug.
0.51
Safety
0.70
Drugs
1
Hyps
1
Papers
17
Monoclonal antibody blocking FcRn-mediated IgG recycling
ABCA1 ATP-binding cassette transporter A1 Approved
Transporter Medium Druggability
Score
0.56
Drug.
0.47
Safety
0.50
Drugs
1
Hyps
6
Papers
0
Small molecule modulators to enhance cholesterol efflux and HDL formation
ABCB1 P-glycoprotein Phase III
Transporter Medium Druggability
Score
0.52
Drug.
0.47
Safety
0.30
Drugs
2
Hyps
1
Papers
17
Small molecule inhibitors to reduce efflux pump activity and enhance CNS drug penetration
SLC16A2 Monocarboxylate transporter 8 Phase I
Transporter Low Druggability
Score
0.44
Drug.
0.39
Safety
0.70
Drugs
1
Hyps
1
Papers
31
Substrate supplementation or transporter modulation
TRAK1_KIF5A Trafficking kinesin protein 1 / Kinesin family mem Phase II
Transporter Low Druggability
Score
0.36
Drug.
0.31
Safety
0.20
Drugs
4
Hyps
1
Papers
28
Therapeutic approaches targeting TRAK1_KIF5A aim to restore or enhance axonal mitochondrial transport by either stabilizing the KIF5A motor protein complex, reducing mutant protein expression through antisense oligonucleotides, or replacing defective protein via gene therapy. This restores cellular energy homeostasis and reduces neuronal degeneration in motor neurons.
SLC17A7 Vesicular glutamate transporter 1 (VGLUT1) Phase III
Transporter Medium Druggability
Score
0.33
Drug.
0.53
Safety
0.60
Drugs
3
Hyps
1
Papers
3
Expression restoration — upregulating SLC17A7 transcription or stabilizing VGLUT1 protein to preserve excitatory synaptic function
SLC16A1 Monocarboxylate transporter 1 (MCT1) Phase II
Transporter Low Druggability
Score
0.28
Drug.
0.38
Safety
0.55
Drugs
3
Hyps
1
Papers
4
Transporter modulation — restoring MCT1/MCT4 balance to normalize astrocyte-neuron metabolic coupling
Exchange | Dashboard